Tesamorelin Dosage Chart & Schedule
A stabilized GHRH analog that is FDA-approved (as Egrifta) to reduce excess visceral adipose tissue in HIV-associated lipodystrophy — one of the few peptides in this index with an approved human indication.
Unlike most entries here, tesamorelin has an FDA-approved regimen: 2 mg subcutaneously once daily (as Egrifta) for HIV-associated lipodystrophy. This is a labeled human dose, not merely a research convention.
Figures describe how Tesamorelin is reported in the research literature and research-community references — not a recommendation for human use. For laboratory research only.
Dosage protocols
Commonly referenced research tiers. Start conservative; every compound and study context differs.
- Frequency
- Once daily
- Weekly total
- 14 mg
- Cycle
- Ongoing per label (clinical)
The FDA-approved Egrifta dose for reducing excess visceral abdominal fat in HIV-associated lipodystrophy; a fixed dose, not titrated.
FDA-approved (Egrifta)
- Tesamorelin is approved as Egrifta / Egrifta SV to reduce excess visceral abdominal fat in HIV-associated lipodystrophy.
- The labeled dose is 2 mg subcutaneously once daily, one of the few approved compounds in this index.
Raises IGF-1
- By increasing growth hormone it raises IGF-1; clinical labeling monitors IGF-1 and cautions in certain populations.
- This oversight distinguishes it from the unapproved secretagogues elsewhere in this index.
Ready to run this protocol?
Dosing is only as good as the vial. Tesamorelin is third-party tested with published COAs from our top-rated source — reconstitute with confidence and skip the guesswork on identity and purity.
Weekly schedule
A typical week on the approved regimen protocol (Once daily).
Dosing day Off
From vial to injection in 6 steps
Wipe both vial tops
Swab the peptide vial and the bacteriostatic-water vial with fresh alcohol and let them dry.
Draw the water
Pull the planned amount of bacteriostatic water (2 mL) into the syringe.
Add it slowly
Run the water down the inside wall of the vial — don't blast the powder. Swirl gently; never shake.
Let it dissolve
Wait until the solution is fully clear, then refrigerate the vial.
Draw your dose
Pull the calculated units on a U-100 insulin syringe.
Store between uses
Keep the reconstituted vial refrigerated and use within its stable window.
Handling & storage
- The approved product is reconstituted with supplied sterile water; a 5 mg research vial + 2 mL bacteriostatic water = 2500 mcg/mL
- Refrigerate reconstituted and use promptly; keep the vial cool and dark
- At the 2 mL mix a 2 mg dose is ~0.8 mL (80 units); a smaller water volume reduces the injection size
Tesamorelin dosing FAQ
How much tesamorelin per day?
Its FDA-approved regimen is 2 mg subcutaneously once daily, about 14 mg/week, for HIV-associated lipodystrophy.
How is tesamorelin reconstituted?
The approved product uses supplied sterile water. For a 5 mg research vial, 2 mL of bacteriostatic water = 2500 mcg/mL, so 2 mg is about 80 units (0.8 mL) on a U-100 syringe.
Does tesamorelin need titration?
Unlike GLP-1 drugs, the approved tesamorelin dose is a fixed 2 mg/day and is not titrated up over time.
Is tesamorelin taken morning or night?
The approved label directs once-daily dosing without a strict time of day; unlike short GHRPs it is a single fixed daily dose.
Sources
Categories: Growth Hormone Secretagogues, GLP-1 & Metabolic · Status: Approved (see notes). This page is educational and for laboratory research use only; it is not medical advice.